大和:核心產品在香港有強勁需求 上調日清(1475.HK)目標價至7.3港元
大和發表研究報告指,日清食品(1475.HK)的核心產品於香港具強勁需求,而在中國大陸對家居煮食及即食產品的需求亦有所上升,隨着去年下半年杯麪產品加價和核心產品的強勁需求,預期今年第一季香港收入增長速度上升,將目標價由6.95港元上調至7.3港元,維持“持有”投資評級。
大和表示,有信心日清於中國內地業務的長期發展,亦預期2020年至2021年日清的中國內地業務收入能有雙位數的增長,並分別上調2020年至2021年中國內地和香港日清即食麪的銷售量2-3%及1-3%,以及上調2020年至2021年日清的收入預測及每股盈利預測分別為2-4%及5-8%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.